Posted in | News | Energy

Sasol Bank Carbon Credits

Sasol has become the first company globally to register a nitrous oxide (N2O) abatement project using secondary catalyst technology to convert the greenhouse gas N2O into harmless nitrogen and oxygen gases.

The project is expected to earn significant income through sales of the resulting carbon credits. A share of these carbon credits will be invested to benefit local community-based sustainable development projects.

"This project reflects our continuous drive to decrease the impact of our operations on the environment through the use of innovative technologies. It offers significant environmental benefits for Sasol, our local communities and South Africa." says Dr Reiner Groh, group general manager, Sasol Chemical Businesses.

Sasol Nitro commissioned its N2O emission abatement technology during the first quarter of 2007. It expects to reduce greenhouse gas emissions equivalent to about a million tons of carbon dioxide a year. One ton of N2O has the greenhouse gas impact equivalent to 310 tons of carbon dioxide.

The project was developed with the assistance of specialist international suppliers MGM International and Heraeus. MGM International is a leader in the development of greenhouse gas emission reduction projects worldwide. Sasol Nitro has a long standing supply agreement with Heraeus, which provides catalyst technology for nitric acid production facilities.

The Sasol Nitro nitrous oxide (N2O) abatement project for the reduction of emissions from its two nitric acid plants based at Sasolburg and Secunda in South Africa is the first of its kind worldwide. This is the first time that a project using secondary catalyst has been registered as a Clean Development Mechanism project in terms of the Kyoto Protocol.

Sasol is achieving significant reductions in its air pollutant emissions and is reducing its overall environmental footprint by reducing emissions and promoting energy and water efficiencies.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.